Abstract
Cytochrome P450s are enzymes which catalyze a large number of biological reactions, for example hydroxylation, N-, O-, S- dealkylation, epoxidation or desamination. Their substrates include fatty acids, steroids or prostaglandins. In addition, a high number of various xenobiotics are metabolized by these enzymes. The enzyme 17α-hydroxylase-C17,20-lyase (P45017, CYP 17, androgen synthase), a cytochrome P450 monooxygenase, is the key enzyme for androgen biosynthesis. It catalyzes the last step of the androgen biosynthesis in the testes and adrenal glands and produces androstenedione and dehydroepiandrosterone from progesterone and pregnenolone. The microsomal enzyme aromatase (CYP19) transforms these androgens to estrone and estradiol. Estrogens stimulate tumor growth in hormone dependent breast cancer. In addition, about 80 percent of prostate cancers are androgen dependent. Selective inhibitors of these enzymes are thus important alternatives to treatment options like antiandrogens or antiestrogens. The present article deals with recent patents (focus on publications from 2000 - 2006) concerning P450 inhibitor design where steroidal substrates are involved. In this context a special focus is provided for CYP17 and CYP19. Mechanisms of action will also be discussed. Inhibitors of CYP11B2 (aldosterone synthase) will also be dealt with.
Keywords: Estrogen, androgen, 17α-hydroxylase-C17, 20-lyase, CYP 17, CYP 19, CYP11B2, steroidal inhibitors, nonsteroidal inhibitors, aromatase
Recent Patents on Anti-Cancer Drug Discovery
Title: Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development
Volume: 2 Issue: 1
Author(s): Eckhard Baston and Frederic R. Leroux
Affiliation:
Keywords: Estrogen, androgen, 17α-hydroxylase-C17, 20-lyase, CYP 17, CYP 19, CYP11B2, steroidal inhibitors, nonsteroidal inhibitors, aromatase
Abstract: Cytochrome P450s are enzymes which catalyze a large number of biological reactions, for example hydroxylation, N-, O-, S- dealkylation, epoxidation or desamination. Their substrates include fatty acids, steroids or prostaglandins. In addition, a high number of various xenobiotics are metabolized by these enzymes. The enzyme 17α-hydroxylase-C17,20-lyase (P45017, CYP 17, androgen synthase), a cytochrome P450 monooxygenase, is the key enzyme for androgen biosynthesis. It catalyzes the last step of the androgen biosynthesis in the testes and adrenal glands and produces androstenedione and dehydroepiandrosterone from progesterone and pregnenolone. The microsomal enzyme aromatase (CYP19) transforms these androgens to estrone and estradiol. Estrogens stimulate tumor growth in hormone dependent breast cancer. In addition, about 80 percent of prostate cancers are androgen dependent. Selective inhibitors of these enzymes are thus important alternatives to treatment options like antiandrogens or antiestrogens. The present article deals with recent patents (focus on publications from 2000 - 2006) concerning P450 inhibitor design where steroidal substrates are involved. In this context a special focus is provided for CYP17 and CYP19. Mechanisms of action will also be discussed. Inhibitors of CYP11B2 (aldosterone synthase) will also be dealt with.
Export Options
About this article
Cite this article as:
Baston Eckhard and Leroux R. Frederic, Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (1) . https://dx.doi.org/10.2174/157489207779561453
DOI https://dx.doi.org/10.2174/157489207779561453 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Quantitative Prediction of Glucuronidation in Humans Using the In Vitro- In Vivo Extrapolation Approach
Current Topics in Medicinal Chemistry Celecoxib in Cancer Therapy and Prevention – Review
Current Drug Targets Synthesis of Mannich Bases by Two Different Methods and Evaluation of their Acetylcholine Esterase and Carbonic Anhydrase Inhibitory Activities
Letters in Drug Design & Discovery Advances in Tumor Targeted Liposomes
Current Molecular Medicine HPC Analysis of Multiple Binding Sites Communication and Allosteric Modulations in Drug Design: The HSP Case Study
Current Drug Targets Neuroinflammation and Immunity: A New Pharmacological Target in Depression
CNS & Neurological Disorders - Drug Targets Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy
Current Medicinal Chemistry HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry Analytical Characterization of Label-Free Immunosensor Subsystems Based on Multi-Walled Carbon Nanotube Array-Modified Gold Interface
Combinatorial Chemistry & High Throughput Screening The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics Hydroxytyrosol Promotes Superoxide Production and Defects in Autophagy Leading to Anti-proliferation and Apoptosis on Human Prostate Cancer Cells
Current Cancer Drug Targets Editorial [ Hot Topic:Recent Concepts on Cancer- and Metastasis-Initiating Cells and Their Therapeutic Implications in the Development of Novel Effective Cancer Therapies(Guest Editors: M. Mimeault and S.K. Batra) ]
Anti-Cancer Agents in Medicinal Chemistry Perspectives in Tissue Microarrays
Combinatorial Chemistry & High Throughput Screening <i>In Vitro</i> and <i>In Vivo</i> Evaluation of Novel DTX-Loaded Multifunctional Heparin-Based Polymeric Micelles Targeting Folate Receptors and Endosomes
Recent Patents on Anti-Cancer Drug Discovery 5-Fluorouracil Derivatives Induce Differentiation Mediated by Tubulin and HLA Class I Modulation
Medicinal Chemistry Vertebrate Protein CTCF and its Multiple Roles in a Large-Scale Regulation of Genome Activity
Current Genomics Traditional Chinese Medicines (TCMs) for Molecular Targeted Therapies of Tumours
Current Drug Discovery Technologies Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine